购物车
- 全部删除
- 您的购物车当前为空
HDAC8-IN-12(compound 5k)作为一个非羟肟酸类,选择性地抑制HDAC8(IC50:0.12 nM),同时对乳腺癌具有显著的抑制效果。该化合物通过促进T细胞激活而引发抗肿瘤免疫反应,可以提高M1型巨噬细胞的数量,减少M2型巨噬细胞的数量。在乳腺癌原位小鼠模型中,HDAC8-IN-12(50 mg/kg)展现出优异的抑制肿瘤生长的能力。
HDAC8-IN-12(compound 5k)作为一个非羟肟酸类,选择性地抑制HDAC8(IC50:0.12 nM),同时对乳腺癌具有显著的抑制效果。该化合物通过促进T细胞激活而引发抗肿瘤免疫反应,可以提高M1型巨噬细胞的数量,减少M2型巨噬细胞的数量。在乳腺癌原位小鼠模型中,HDAC8-IN-12(50 mg/kg)展现出优异的抑制肿瘤生长的能力。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 10-14周 | |
50 mg | 询价 | 10-14周 |
产品描述 | HDAC8-IN-12 (compound 5k), a non-hydroxamic acid derivative, serves as a selective HDAC8 inhibitor with an IC 50 of 0.12 nM and demonstrates potent efficacy against breast cancer. This compound enhances anti-tumor immunity by activating T cells, elevating M1 macrophage levels, and reducing M2 macrophage proportions. In an orthotopic mouse model of breast cancer, HDAC8-IN-12, administered at 50 mg/kg, effectively suppresses tumor growth. |
分子量 | 331.32 |
分子式 | C16H17N3O5 |
CAS No. | 3028095-13-5 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容